Hey all!
As opposed to the trading chatter that's permeating all the other threads, I thought that it would be useful to have a thread where we could exchange ideas about Remestemcel-L's MOA and the possible interaction in-vivo in the treatment of COVID-19 ARDS.
As a primer, here is the recent slide showing how Rem-L responds to inflammation.
My question is, in C-19 ARDS, patients have displayed elevated serum cytokines (particularly IL-6 and TNFa) among other things. Do you reckon there are factors in play that Rem-L might modulate?
(NON-TRADING) COVID-19 ARDS DISCUSSION
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |